Alveron Pharma BV raises a further EUR 3.9 million to progress first in class drug
Alveron’s drug is unique as it reverses the effects of all the major anticoagulants (including all DOACs and vitamin K antagonists) and platelet aggregation inhibitors like clopidogrel.